185 related articles for article (PubMed ID: 35000652)
1. Predictors of pharmacotherapy outcomes for body dysmorphic disorder: a machine learning approach.
Curtiss JE; Bernstein EE; Wilhelm S; Phillips KA
Psychol Med; 2023 Jun; 53(8):3366-3376. PubMed ID: 35000652
[TBL] [Abstract][Full Text] [Related]
2. Predictors of remission from body dysmorphic disorder after internet-delivered cognitive behavior therapy: a machine learning approach.
Flygare O; Enander J; Andersson E; Ljótsson B; Ivanov VZ; Mataix-Cols D; Rück C
BMC Psychiatry; 2020 May; 20(1):247. PubMed ID: 32429939
[TBL] [Abstract][Full Text] [Related]
3. Personality as a Predictor of Treatment Response to Escitalopram in Adults With Body Dysmorphic Disorder.
Fang A; Porth R; Phillips KA; Wilhelm S
J Psychiatr Pract; 2019 Sep; 25(5):347-357. PubMed ID: 31505519
[TBL] [Abstract][Full Text] [Related]
4. Machine learning to predict clinical remission in depressed patients after acute phase selective serotonin reuptake inhibitor treatment.
Zhou S; Ma Q; Lou Y; Lv X; Tian H; Wei J; Zhang K; Zhu G; Chen Q; Si T; Wang G; Wang X; Zhang N; Huang Y; Liu Q; Yu X
J Affect Disord; 2021 May; 287():372-379. PubMed ID: 33836365
[TBL] [Abstract][Full Text] [Related]
5. Treating body dysmorphic disorder with medication: evidence, misconceptions, and a suggested approach.
Phillips KA; Hollander E
Body Image; 2008 Mar; 5(1):13-27. PubMed ID: 18325859
[TBL] [Abstract][Full Text] [Related]
6. An open-label study of escitalopram in body dysmorphic disorder.
Phillips KA
Int Clin Psychopharmacol; 2006 May; 21(3):177-9. PubMed ID: 16528140
[TBL] [Abstract][Full Text] [Related]
7. A 4-year prospective observational follow-up study of course and predictors of course in body dysmorphic disorder.
Phillips KA; Menard W; Quinn E; Didie ER; Stout RL
Psychol Med; 2013 May; 43(5):1109-17. PubMed ID: 23171833
[TBL] [Abstract][Full Text] [Related]
8. Empirically defining treatment response and remission in body dysmorphic disorder.
Fernández de la Cruz L; Enander J; Rück C; Wilhelm S; Phillips KA; Steketee G; Sarvode Mothi S; Krebs G; Bowyer L; Monzani B; Veale D; Mataix-Cols D
Psychol Med; 2021 Jan; 51(1):83-89. PubMed ID: 31662124
[TBL] [Abstract][Full Text] [Related]
9. Can machine learning predict pharmacotherapy outcomes? An application study in osteoporosis.
Lin YT; Chu CY; Hung KS; Lu CH; Bednarczyk EM; Chen HY
Comput Methods Programs Biomed; 2022 Oct; 225():107028. PubMed ID: 35930862
[TBL] [Abstract][Full Text] [Related]
10. Pharmacotherapy in body dysmorphic disorder: relapse prevention and novel treatments.
Dong N; Nezgovorova V; Hong K; Hollander E
Expert Opin Pharmacother; 2019 Jul; 20(10):1211-1219. PubMed ID: 31038370
[No Abstract] [Full Text] [Related]
11. Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorder.
Schneier FR; Feusner J; Wheaton MG; Gomez GJ; Cornejo G; Naraindas AM; Hellerstein DJ
J Psychiatr Res; 2023 May; 161():364-370. PubMed ID: 37004409
[TBL] [Abstract][Full Text] [Related]
12. Predictors and moderators of symptom change during cognitive-behavioral therapy or supportive psychotherapy for body dysmorphic disorder.
Phillips KA; Greenberg JL; Hoeppner SS; Weingarden H; O'Keefe S; Keshaviah A; Schoenfeld DA; Wilhelm S
J Affect Disord; 2021 May; 287():34-40. PubMed ID: 33773357
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of pharmacotherapy for body dysmorphic disorder: a chart-review study.
Phillips KA; Albertini RS; Siniscalchi JM; Khan A; Robinson M
J Clin Psychiatry; 2001 Sep; 62(9):721-7. PubMed ID: 11681769
[TBL] [Abstract][Full Text] [Related]
14. Neural Correlates of Response to Pharmacotherapy in Obsessive-Compulsive Disorder: Individualized Cortical Morphology-Based Structural Covariance.
Yun JY; Jang JH; Kim SN; Jung WH; Kwon JS
Prog Neuropsychopharmacol Biol Psychiatry; 2015 Dec; 63():126-33. PubMed ID: 26116795
[TBL] [Abstract][Full Text] [Related]
15. Cognitive-behavioral therapy for youth with body dysmorphic disorder: current status and future directions.
Phillips KA; Rogers J
Child Adolesc Psychiatr Clin N Am; 2011 Apr; 20(2):287-304. PubMed ID: 21440856
[TBL] [Abstract][Full Text] [Related]
16. Aripiprazole as an augmentation agent in treatment-resistant body dysmorphic disorder.
Uzun O; Ozdemir B
Clin Drug Investig; 2010; 30(10):707-10. PubMed ID: 20701402
[TBL] [Abstract][Full Text] [Related]
17. An open study of buspirone augmentation of serotonin-reuptake inhibitors in body dysmorphic disorder.
Phillips KA
Psychopharmacol Bull; 1996; 32(1):175-80. PubMed ID: 8927669
[TBL] [Abstract][Full Text] [Related]
18. Body dysmorphic disorder.
Fang A; Matheny NL; Wilhelm S
Psychiatr Clin North Am; 2014 Sep; 37(3):287-300. PubMed ID: 25150563
[TBL] [Abstract][Full Text] [Related]
19. An open-label study of citalopram in body dysmorphic disorder.
Phillips KA; Najjar F
J Clin Psychiatry; 2003 Jun; 64(6):715-20. PubMed ID: 12823088
[TBL] [Abstract][Full Text] [Related]
20. Delusionality and response to open-label fluvoxamine in body dysmorphic disorder.
Phillips KA; McElroy SL; Dwight MM; Eisen JL; Rasmussen SA
J Clin Psychiatry; 2001 Feb; 62(2):87-91. PubMed ID: 11247107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
